Download PDF
Neuropediatrics 2021; 52(06): 431-440
DOI: 10.1055/s-0040-1722681
Original Article

Clinico-Radiological Correlation in 26 Egyptian Children with Glutaric Acidemia Type 1

Abdelrahim A. Sadek
1   Neuropsychiatry Unit, Department of Pediatrics, Faculty of Medicine, Sohag University, Sohag, Egypt
,
Mohammed A. Aladawy
2   Neurology Unit, Department of Pediatrics, Faculty of Medicine, Al-Azhar University, Assiut, Egypt
,
Rofaida M. Magdy
3   Metabolic and Genetic Unit, Department of Pediatrics, Faculty of Medicine, Sohag University, Sohag, Egypt
,
Tarek M. M. Mansour
4   Department of Radio-diagnosis, Faculty of Medicine, Al-Azhar University, Assiut, Egypt
,
Amr A. Othman
1   Neuropsychiatry Unit, Department of Pediatrics, Faculty of Medicine, Sohag University, Sohag, Egypt
,
Bahaa Hawary
5   Neurology Unit, Department of Pediatrics, Faculty of Medicine, Aswan University, Aswan Egypt
,
Mohamed F. Ibrahim
2   Neurology Unit, Department of Pediatrics, Faculty of Medicine, Al-Azhar University, Assiut, Egypt
,
Mohammed H. Hassan
6   Department of Medical Biochemistry, Faculty of Medicine, South Valley University, Qena, Egypt
,
Elsayed Abdelkreem
7   Department of Pediatrics, Faculty of Medicine, Sohag University, Sohag, Egypt
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Background Glutaric acidemia type 1 (GA1) is an inherited neurometabolic disease with significant morbidity. However, neuro-radiological correlation is not completely understood.

Objective The study aimed to characterize the neuroimaging findings and their association with neurological phenotype in GA1 children.

Methods Twenty-six Egyptian children (median age = 12 months) diagnosed with GA1 underwent clinical evaluation and brain magnetic resonance imaging (MRI). We objectively assessed the severity of neurological phenotype at the time of MRI using movement disorder (MD) and morbidity scores. Evaluation of brain MRI abnormalities followed a systematic and region-specific scoring approach. Brain MRI findings and scores were correlated with MD and morbidity scores, disease onset, and presence of seizures.

Results Fifteen (57.7%) cases had insidious onset, eight (30.8%) manifested acute onset, whereas three (11.5%) were asymptomatic. Ten (38.5%) cases had seizures, five of which had no acute encephalopathic crisis. Putamen and caudate abnormalities (found in all acute onset, 93.3 and 73.3% of insidious onset, and one of three asymptomatic cases) were significantly related to MD (p = 0.007 and 0.013) and morbidity (p = 0.005 and 0.003) scores. Globus pallidus abnormalities (50% of acute onset, 46.7% of insidious onset, and one of three of asymptomatic cases) were significantly associated with morbidity score (p = 0.023). Other MRI brain abnormalities as well as gray and white matter score showed no significant association with neurological phenotype. Younger age at onset, acute onset, and seizures were significantly associated with worse neurological manifestations.

Conclusion Patients with GA1 manifest characteristic and region-specific brain MRI abnormalities, but only striatal affection appears to correlate with neurological phenotype.

Keywords

glutaric acidemia type 1 - movement disorder - magnetic resonance imaging - seizures - striatal injury

Supplementary Material



Publication History

Received: 23 August 2020

Accepted: 03 November 2020

Article published online:
23 February 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Boy N, Mühlhausen C, Maier EM. et al; Additional individual contributors. Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision. J Inherit Metab Dis 2017; 40 (01) 75-101
    CrossrefPubMedGoogle Scholar
  • 2 Kölker S, Garbade SF, Greenberg CR. et al. Natural history, outcome, and treatment efficacy in children and adults with glutaryl-CoA dehydrogenase deficiency. Pediatr Res 2006; 59 (06) 840-847
    CrossrefPubMedGoogle Scholar
  • 3 Boy N, Garbade SF, Mengler K, Kölker S. Effect of newborn screening and adherence to recommended treatment on clinical outcome in glutaric aciduria type 1: a meta-analysis. Neuropediatrics 2019; 50: S1-S55
    PubMedGoogle Scholar
  • 4 Lindner M, Kölker S, Schulze A, Christensen E, Greenberg CR, Hoffmann GF. Neonatal screening for glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis 2004; 27 (06) 851-859
    CrossrefPubMedGoogle Scholar
  • 5 Boy N, Garbade SF, Heringer J, Seitz A, Kölker S, Harting I. Patterns, evolution, and severity of striatal injury in insidious- vs acute-onset glutaric aciduria type 1. J Inherit Metab Dis 2019; 42 (01) 117-127
    CrossrefPubMedGoogle Scholar
  • 6 Külkens S, Harting I, Sauer S. et al. Late-onset neurologic disease in glutaryl-CoA dehydrogenase deficiency. Neurology 2005; 64 (12) 2142-2144
    CrossrefPubMedGoogle Scholar
  • 7 Baric I, Wagner L, Feyh P, Liesert M, Buckel W, Hoffmann GF. Sensitivity and specificity of free and total glutaric acid and 3-hydroxyglutaric acid measurements by stable-isotope dilution assays for the diagnosis of glutaric aciduria type I. J Inherit Metab Dis 1999; 22 (08) 867-881
    CrossrefPubMedGoogle Scholar
  • 8 Boy N, Mengler K, Thimm E. et al. Newborn screening: a disease-changing intervention for glutaric aciduria type 1. Ann Neurol 2018; 83 (05) 970-979
    CrossrefPubMedGoogle Scholar
  • 9 Harting I, Neumaier-Probst E, Seitz A. et al. Dynamic changes of striatal and extrastriatal abnormalities in glutaric aciduria type I. Brain 2009; 132 (Pt 7): 1764-1782
    CrossrefPubMedGoogle Scholar
  • 10 Sauer SW, Opp S, Hoffmann GF, Koeller DM, Okun JG, Kölker S. Therapeutic modulation of cerebral L-lysine metabolism in a mouse model for glutaric aciduria type I. Brain 2011; 134 (Pt 1): 157-170
    CrossrefPubMedGoogle Scholar
  • 11 Boy N, Mengler K, Heringer-Seifert J, Hoffmann GF, Garbade SF, Kölker S. Impact of newborn screening and quality of therapy on the neurological outcome in glutaric aciduria type 1: a meta-analysis. Genet Med 2021; 23 (01) 13-21
    CrossrefPubMedGoogle Scholar
  • 12 Twomey EL, Naughten ER, Donoghue VB, Ryan S. Neuroimaging findings in glutaric aciduria type 1. Pediatr Radiol 2003; 33 (12) 823-830
    CrossrefPubMedGoogle Scholar
  • 13 Mohammad SA, Abdelkhalek HS, Ahmed KA, Zaki OK. Glutaric aciduria type 1: neuroimaging features with clinical correlation. Pediatr Radiol 2015; 45 (11) 1696-1705
    CrossrefPubMedGoogle Scholar
  • 14 Garbade SF, Greenberg CR, Demirkol M. et al. Unravelling the complex MRI pattern in glutaric aciduria type I using statistical models-a cohort study in 180 patients. J Inherit Metab Dis 2014; 37 (05) 763-773
    CrossrefPubMedGoogle Scholar
  • 15 Strauss KA, Lazovic J, Wintermark M, Morton DH. Multimodal imaging of striatal degeneration in Amish patients with glutaryl-CoA dehydrogenase deficiency. Brain 2007; 130 (Pt 7): 1905-1920
    CrossrefPubMedGoogle Scholar
  • 16 Hassan FA, El-Mougy F, Sharaf SA. et al. Inborn errors of metabolism detectable by tandem mass spectrometry in Egypt: The first newborn screening pilot study. J Med Screen 2016; 23 (03) 124-129
    CrossrefPubMedGoogle Scholar
  • 17 Zayed H, El Khayat H, Tomoum H. et al. Clinical, biochemical, neuroradiological and molecular characterization of Egyptian patients with glutaric acidemia type 1. Metab Brain Dis 2019; 34 (04) 1231-1241
    CrossrefPubMedGoogle Scholar
  • 18 van der Knaap MS, Breiter SN, Naidu S, Hart AAM, Valk J. Defining and categorizing leukoencephalopathies of unknown origin: MR imaging approach. Radiology 1999; 213 (01) 121-133
    CrossrefPubMedGoogle Scholar
  • 19 Chen CY, Zimmerman RA, Faro S. et al. MR of the cerebral operculum: topographic identification and measurement of interopercular distances in healthy infants and children. AJNR Am J Neuroradiol 1995; 16 (08) 1677-1687
    PubMedGoogle Scholar
  • 20 van der Knaap MS, Valk J. eds. Magnetic Resonance of Myelination and Myelin Disorders. 3rd edition. Springer Berlin Heidelberg; 2005: 37-65
    CrossrefGoogle Scholar
  • 21 Brismar J, Ozand PT. CT and MR of the brain in glutaric acidemia type I: a review of 59 published cases and a report of 5 new patients. AJNR Am J Neuroradiol 1995; 16 (04) 675-683
    PubMedGoogle Scholar
  • 22 Soffer D, Amir N, Elpeleg ON, Gomori JM, Shalev RS, Gottschalk-Sabag S. Striatal degeneration and spongy myelinopathy in glutaric acidemia. J Neurol Sci 1992; 107 (02) 199-204
    CrossrefPubMedGoogle Scholar
  • 23 Strauss KA, Donnelly P, Wintermark M. Cerebral haemodynamics in patients with glutaryl-coenzyme A dehydrogenase deficiency. Brain 2010; 133 (Pt 1): 76-92
    CrossrefPubMedGoogle Scholar
  • 24 Harting I, Boy N, Heringer J. et al. (1)H-MRS in glutaric aciduria type 1: impact of biochemical phenotype and age on the cerebral accumulation of neurotoxic metabolites. J Inherit Metab Dis 2015; 38 (05) 829-838
    CrossrefPubMedGoogle Scholar
  • 25 Kölker S, Garcia-Cazorla A, Valayannopoulos V. et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentation. J Inherit Metab Dis 2015; 38 (06) 1041-1057
    CrossrefPubMedGoogle Scholar
  • 26 Haworth JC, Booth FA, Chudley AE. et al. Phenotypic variability in glutaric aciduria type I: report of fourteen cases in five Canadian Indian kindreds. J Pediatr 1991; 118 (01) 52-58
    CrossrefPubMedGoogle Scholar
  • 27 McClelland VM, Bakalinova DB, Hendriksz C, Singh RP. Glutaric aciduria type 1 presenting with epilepsy. Dev Med Child Neurol 2009; 51 (03) 235-239
    CrossrefPubMedGoogle Scholar